Highlights {#S001}
==========

Repeated exposure to thioacetamide results in HCC in rats.Sodium ascorbate is a strong water-soluble antioxidant with cytotoxic activity.Sodium ascorbate activates extrinsic and intrinsic apoptotic pathway in tumor cells.It protects normal hepatic cells by antioxidant, anti-inflammatory and anti-apoptotic effects.

1.. Introduction {#S002}
================

The incidence of hepatocellular carcinoma (HCC) has significantly elevated worldwide (for review \[[@CIT0001]\]). The expression of both nuclear factors and inflammatory cytokines plays a major role in the incidence of HCC \[[@CIT0002]\]. However, the inflammatory microenvironment is the major cause of intrinsic heterogeneity of cancer cells and genomic instability \[[@CIT0005]\]. In addition, extracellular matrix (ECM) is formed of many heterogeneous molecules. It serves as a store for nuclear factors, inflammatory cells, angiogenesis promoters and many biologically active molecules \[[@CIT0006]\]. The release of all these macromolecules activates these pathways leading to pathogenesis and progression of HCC through controlling cells proliferation and differentiation leading to tumor cells invasion and metastasis \[[@CIT0007]\]. HCC has been linked with a high rate of mortality \[[@CIT0008]\]. However, more investigations are needed to find out new therapeutic drugs for the treatment of HCC patients.

Ascorbic acid is considered a strong water-soluble antioxidant vitamin, which was reported recently to produce a highly selective cytotoxic activity against many tumors without affecting normal cells \[[@CIT0009]\]. This selective effect could be explained by several mechanisms such as reduction of the mitochondrial sensitivity to hydrogen peroxide \[[@CIT0010]\], inhibition of catalase and superoxide dismutase activity \[[@CIT0011]\], enhancement of glycolytic metabolism and blockage of the activity of MMP9 \[[@CIT0012]\]. It can propagate cancer cell apoptosis without introducing any changes in cellular redox status in HepG2 cells \[[@CIT0013]\] accompanied by influencing cell proliferation \[[@CIT0014]\].

Recently, we found that sodium ascorbate produced cytotoxic activity through blocking sulfatase-2 and restoring heparan sulfate proteoglycans (HSPGs) associated with reducing glypican-3/IGF-2 and deactivation of the inflammatory pathway \[[@CIT0015]\]. However, there is no available information about the effect of sodium ascorbate on the apoptotic pathway in HCC. Therefore, we aimed to discover the selective cytotoxic activity of sodium ascorbate and its relation to the inflammatory pathway in experimentally induced HCC in rats and in HepG2 cells.

2.. Materials and methods {#S003}
=========================

2.1.. Animals {#S003-S2001}
-------------

The local ethical committee in the University of Tabuk approved the animal protocol under number UT-42-3-2018. Thirty-two male Sprague--Dawely rats were kept under standard conditions and regular 12 h light/12 h dark cycle. Rats were classified into four groups with eight rats in each group.

### 2.1.1.. Control group {#S003-S2001-S3001}

Rats were injected with phosphate-buffered saline (PBS, 10 mM, pH 7.4) intraperitoneally (ip).

### 2.1.2.. Ascorbate-treated control group {#S003-S2001-S3002}

Rats were treated with 100 mg/kg sodium ascorbate (Sigma Aldrich Chemicals Co., St Louise, MO, USA) twice weekly for 16 weeks via ip injection.

### 2.1.3.. HCC group {#S003-S2001-S3003}

Rats received 200 mg/kg thioacetamide (Tocris, Bristol, UK), ip, twice weekly for 16 weeks.

### 2.1.4.. Ascorbate-treated HCC group {#S003-S2001-S3004}

Rats were given both 200 mg/kg thioacetamide, ip, and 100 mg/kg sodium ascorbate, ip, twice weekly for 16 weeks.

The doses and time course were in consistent with previous studies \[[@CIT0008],[@CIT0012],[@CIT0015]\].

2.2.. Morphologic analysis of hepatic tissue {#S003-S2002}
--------------------------------------------

Fixed liver sections were cut into 5 µm thickness sections. The sections were stained with Mayer's hematoxylin and eosin (H&E). Sections were examined in a masked manner and photographed using Nikon Digital Camera (Japan).

2.3.. Assessment of oxidative stress {#S003-S2003}
------------------------------------

Oxidative stress was assessed by determining the concentration of hydrogen peroxide by horseradish peroxidase method \[[@CIT0021]\]. Moreover, the concentration of superoxide anion concentration was analyzed by nitroblue tetrazolium method \[[@CIT0022]\].

2.4.. Enzyme-linked immunosorbent assay {#S003-S2004}
---------------------------------------

The levels of biochemical parameters were determined by Enzyme-linked immunosorbent (ELISA) assay using a commercially available TNF-α (eBioscience Inc., San Diego, CA, USA) and α-fetoprotein (USCN Life Science Inc., Houston, TX, USA).

2.5.. Quantitative real-time polymerase chain reaction {#S003-S2005}
------------------------------------------------------

The PCR analysis was performed as described previously by our group \[[@CIT0015]\]. In HepG2 cells, the sequence of NFκB forward primer 5′-ACCCTGACCTTGCCTATTTG-3′ and reverse primer 5′-GAAAAGCTGTAAACATGAGCCG-3′, for Nrf2 forward primer 5′-CAGCGACGGAAAGAGTATGA-3′ and reverse primer 5′-TGGGCAACCTGGGAGTAG-3′ and for GAPDH the forward primer 5′-AGAAGGCTGGGGCTCATTTG-3′ and reverse primer 5′-GAAGCTTCTGTTGGCTCCC-3′. In rats, for Nrf2, the forward primer 5′-GAGACGGCCATGACTGAT-3′ and reverse primer, 5′-GTGAGGGGATCGATGAGTAA-3′, for NFκB, the forward primer, 5′- GGAAGTGAGAGAGTGAGCGAGAG -3′ and reverse primer 5′-GGGTGGCGAAACCTCCTC -3′; for caspase-3, forward primer 5′-GATCACAGCAAAAGGAGCAGT-3′ and reverse primer 3′-CTCCACTGTCTGTCTCAAT-5′, caspase-8: forward primer 5′-CTGGGAAGGATCGACGATTA-3′ and reverse primer 5′-TGGTCACCTCATCCAAAACA-3′, for caspase-9 forward primer 5′-GAATTCCAGCAATCCGCTAGCCATGGAGG-3′ and reverse primer 5′-GAATTCAACTCATGAAGTTTAAAGAACAG-3′ and for GAPDH, the forward primer 5′- CCATCAACGACCCCTTCATT-3′ and reverse primer 5′- CACGACATACTCAGCACCAGC-3′.

2.6.. Estimation of caspases activity {#S003-S2006}
-------------------------------------

The enzyme activities of caspase-3, -8 and -9 was measured using commercially available kits (Abcam, Cambridge, MA, USA).

2.7.. Cell lines {#S003-S2007}
----------------

The human HCC, HepG2 (American Type Culture Collection, ATCC, Manassas, VA, USA).

### 2.7.1.. Cell lysates {#S003-S2007-S3001}

HepG2 cells were extracted by 50 mM Tris--HCl lysis buffer, pH 7.4, supplemented with 0.5% Triton-X 100, 150 mM NaCl and protease inhibitor cocktail. Protein level in HepG2 cells was determined (Bradford reagent, BioRad, Hercules, CA, USA).

### 2.7.2.. MTT assay {#S003-S2007-S3002}

A 96-well plate containing HepG2 cells (1 × 10^4^) were incubated in a humidified CO~2~ incubator at 37°C for 24 h. Cells were treated with both sodium ascorbate and cisplatin (50, 100 and 250 µM) and kept in humidified CO~2~ incubator for 48 h. The viability was assessed using MTT (Sigma Aldrich Chemicals Co., St Louise, MO, USA) as described previously \[[@CIT0012],[@CIT0016],[@CIT0023],[@CIT0024]\]. While, time course and doses of sodium ascorbate and cisplatin were in the range of previous studies \[[@CIT0012],[@CIT0025],[@CIT0026]\].

### 2.7.3.. Cytotoxicity with lactate dehydrogenase {#S003-S2007-S3003}

Cell cytotoxicity was performed using lactate dehydrogenase reagent as described by our group \[[@CIT0015],[@CIT0027]\]. Triton-X 100 was used as a positive cytotoxicity control.

2.8.. Statistical analysis {#S003-S2008}
--------------------------

For quantitative variables, the mean ± standard error was used. The normality of distribution of samples were determined by the Kolmogorov--Smirnov test. One-way ANOVA was used for comparison between the groups followed by the *post hoc* Bonferroni correction test was calculated. SPSS version 20 (Chicago, IL, USA) was used. Statistical significance was predefined as *p* ≤ .05.

3.. Results {#S004}
===========

3.1.. Effect of sodium ascorbate on HCC-induced oxidative stress {#S004-S2001}
----------------------------------------------------------------

Treating HCC rats with sodium ascorbate significantly reversed HCC-induced reduction in the gene expression of Nrf2 without affecting the control group. Moreover, treatment of HepG2 cells with sodium ascorbate resulted in elevated gene expression of Nrf2. However, treating HepG2 cells with cisplatin significantly reduced the gene expression of Nrf2 ([Figure 1](#F0001){ref-type="fig"}). Figure 1.Effect of 100 mg/kg sodium ascorbate on hepatic gene expression of Nrf2 (A). Effect of 50, 100 and 250 μM sodium ascorbate and cisplatin on the gene expression of Nrf2 (B) in HepG2. \*Significant difference when compared with the control group of HepG2 cells at *p *\< .05. ^\#^Significant difference when compared with the HCC group or HepG2 cells treated with cisplatin at *p *\< .05.

As shown in [Figure 2](#F0002){ref-type="fig"}, we found that sodium ascorbate significantly reduced HCC-induced elevation in both hydrogen peroxide and superoxide anion when compared with the HCC group. However, treatment of HepG2 cell with ascorbate significantly reduced hydrogen peroxide and superoxide anion, while treating HepG2 cells with cisplatin significantly elevated both superoxide anion and hydrogen peroxide. Figure 2.Effect of 100 mg/kg sodium ascorbate on hepatic hydrogen peroxide (A) and hepatic superoxide anion (C) *in vivo*. Effect of 50, 100 and 250 μM sodium ascorbate and cisplatin on the concentration of hydrogen peroxide (B) and superoxide anion (D) in HepG2. \* Significant difference when compared with the control group or HepG2 cells at *p *\< .05. ^\#^Significant difference when compared with the HCC group or HepG2 cells treated with cisplatin at *p *\< .05.

3.2.. Sodium ascorbate attenuated HCC-induced activation of inflammatory pathway {#S004-S2002}
--------------------------------------------------------------------------------

Treatment of HCC rats with sodium ascorbate produced a significant reduction in gene expression of NFκB as well as protein expression of TNF-α; however, the levels are still higher than the control group. In parallel, a high dose of sodium ascorbate reduced NFκB gene expression associated with dose-dependent reduction in protein release of TNF-α in HepG2 cells. However, the addition of cisplatin to HepG2 cells caused a dose-dependent elevation in gene expression of NFκB and protein release of TNF-α ([Figure 3](#F0003){ref-type="fig"}). Figure 3.Effect of 100 mg/kg sodium ascorbate on relative hepatic gene expression of NFκB (A) and TNF-α level (C) *in vivo*. Effect of 50, 100 and 250 μM sodium ascorbate and cisplatin on the gene expression of NFκB (B) and TNF-α level (D) in HepG2. \*Significant difference when compared with the control group or HepG2 cells at *p *\< .05. ^\#^Significant difference when compared with the HCC group or HepG2 cells treated with cisplatin at *p *\< .05.

3.3.. Effect of sodium ascorbate on HCC-induced elevation in caspases *in vivo* {#S004-S2003}
-------------------------------------------------------------------------------

As shown in [Figure 4](#F0004){ref-type="fig"}, sodium ascorbate significantly reduced gene expression and enzyme activity of caspase-3, -8 and -9 in the HCC group without affecting the control group. However, sodium ascorbate reduced gene expression and enzyme activity of caspase-9 to levels of control rats. Figure 4.Effect of 100 mg/kg sodium ascorbate on hepatic gene expression of caspase-3 (A), caspase-8 (C) and caspase-9 (E) *in vivo* as well as the hepatic enzyme activity of caspase-3 (B), caspase-8 (D) and caspase-9 (F). \*Significant difference when compared with the control group at *p *\< .05. \# Significant difference when compared with the HCC group at *p *\< .05.

3.4.. Effect of sodium ascorbate on apoptosis in HepG2 cells {#S004-S2004}
------------------------------------------------------------

Treatment of HepG2 cells with sodium ascorbate produced a dose-dependent slight increase in activities of caspase-3, -8 and -9 ([Figure 5](#F0005){ref-type="fig"}). Moreover, cisplatin pro­duced significantly higher effects on the activity of the three caspases in HepG2 cells when compared with sodium ascorbate with the same dose. Figure 5.Effect of 50, 100 and 250 μM sodium ascorbate and cisplatin on the activity of caspase-3 (A), caspase-8 (B) and caspase-9 (C) in HepG2. \*Significant difference when compared with HepG2 cells at *p *\< 0.05. ^\#^Significant difference when compared with cisplatin-treated HepG2 cells at *p *\< .05.

3.5.. *In vivo* antitumor activity of sodium ascorbate {#S004-S2005}
------------------------------------------------------

Sodium ascorbate significantly reduced the average number of nodules in the liver when compared with HCC rats as well as it reduced serum level of α-fetoprotein but still higher than the control group ([Figure 6](#F0006){ref-type="fig"}(A and B)). Figure 6.Effect of 100 mg/kg sodium ascorbate on average number of nodules (A) and serum level of α-fetoprotein (B) *in vivo*. In addition, hepatic sections stained with hematoxylin/eosin in different rat groups (C). Thick black arrow represented ground glass hepatocytes characterized by homogenous pink or vacuolated cytoplasm. Thin black arrows represented apoptotic nuclei. Yellow arrow represented necrotic hepatocytes at the periphery of the nodules. Scale bar 100 µm. \*Significant difference when compared with the control group at *p *\< 0.05. ^\#^Significant difference when compared with the HCC group at *p *\< .05.

3.6.. Hepatoprotective effects of sodium ascorbate {#S004-S2006}
--------------------------------------------------

Examination of hepatic sections of HCC rats stained with hematoxylin/eosin showed marked inflammatory cells infiltration, apoptotic changes and vacuolations of hepatocytes. The hepatocytes on the periphery of the nodules are necrotic (yellow arrows). All these changes were significantly ameliorated by sodium ascorbate ([Figure 6](#F0006){ref-type="fig"}(C)).

3.7.. Cytotoxic studies of sodium ascorbate {#S004-S2007}
-------------------------------------------

We found that sodium ascorbate decreased HepG2 survival and enhanced HepG2 cytotoxicity in a dose-dependent manner. Cisplatin produced similar effects but significantly higher than sodium ascorbate ([Figure 7](#F0007){ref-type="fig"}). Figure 7.Effect of 50, 100 and 250 μM sodium ascorbate and cisplatin on HepG2 cell survival (A) and HepG2 cell cytotoxicity (B). \*Significant difference when compared with HepG2 cells at *p *\< 0.05. ^\#^Significant difference when compared with cisplatin-treated HepG2 cells at *p *\< .05.

4.. Discussion {#S005}
==============

Ascorbic acid is required for the control and maintenance of many cellular functions. Many previous reports illustrated the importance of sodium ascorbate in cancer treatment due to its ability to affect cell proliferation associated with its ability to enhance well-being state of patients \[[@CIT0014]\].

Oxidative stress is a key player in both the development and progression of HCC. Oxidative stress was reported to affect cell proliferation, apoptosis and cell cycle \[[@CIT0012],[@CIT0028]\]. Oxidative stress activates mitogen-activated protein kinases with subsequent effect on the regulation of cell growth and transformation \[[@CIT0029]\]. Oxidative stress influences the formation of ECM and cell-to-cell interaction \[[@CIT0030]\]. However, we found that treatment of HCC rats as well as HepG2 cells with sodium ascorbate attenuated elevated levels of oxidative stress in a dose-dependent manner. However, ascorbate was previously reported to induce cell apoptosis without changes in cellular redox status in HepG2 \[[@CIT0013]\].

Interestingly, reactive oxygen species are activators of autophagy and other stress response systems such as nuclear factor (erythroid-derived 2)-like 2 (Nrf2) \[[@CIT0031]\]. Accumulation of Nrf2 in cytoplasm enhances nuclear migration and activates transcription of antioxidant and detoxification compounds that promote cellular response to oxidative stress \[[@CIT0032]\]. We found that sodium ascorbate reversed HCC-induced reduction in gene expression of Nrf2. However, no previous study illustrated the effect of sodium ascorbate on gene expression of Nrf2 in HCC models.

HCC is an inflammation-based carcinogenic process as over than 90% of HCC patients developed chronic liver damage \[[@CIT0033],[@CIT0034]\]. NFκB mediates pro-inflammatory cytokines and is linked with many types of cancer, including HCC \[[@CIT0030],[@CIT0035]\]. It induces the transcription of pro-inflammatory cytokines \[[@CIT0036],[@CIT0037]\]. In addition, many inflammatory cytokines, such as TNF-α, IL-1α, IL-1β, IL-6 and IL-8, have been associated with chronic liver inflammation \[[@CIT0038],[@CIT0039]\]. One of these inflammatory cytokines, TNF-α, is considered as an established marker of DNA damage \[[@CIT0040]\]. However, we found that treatment of HCC rats and HepG2 with sodium ascorbate reduced gene expression of NFκB associated with a reduction in protein levels of TNF-α. On the other hand, cisplatin elevated pro-inflammation cytokines *in vitro*, because it is well-known inflammation inducer \[[@CIT0041],[@CIT0042]\].

We observed significant elevations in hepatic activities of caspase-3, -8 and -9 in HCC rats, which was inhibited by sodium ascorbate. Caspase-8 is well known in activating extrinsic cell death by activating transmembrane receptor interactions. The extrinsic apoptosis pathway can be initiated by the binding of specific ligands such as TNF-α \[[@CIT0043]\]. When activated, caspase-8 will be released inside the cytoplasm and initiates the cleavage of caspase-3 \[[@CIT0044]\]. However, we discovered a significant elevation in TNF-α associated with elevated caspase-8, in HCC rats. However, caspase-9 is a major part in the intrinsic cell death pathway \[[@CIT0045]\]. In response to mitochondrial stress, caspase-9 is released and activated producing to various pathological conditions with subsequent activation of caspase-3 \[[@CIT0046]\].

We observed an elevated superoxide anion and hydrogen peroxide levels that were associated with high caspase-9 leading to enhancement of the intrinsic cell death pathway. All these effects were attenuated by sodium ascorbate. These findings strongly suggest that sodium ascorbate inhibits oxidant-induced apoptotic cell death in hepatic cells. In addition, sodium ascorbate reduced inflammatory pathway with a subsequent reduction in the activity of caspase-8. Therefore, sodium ascorbate ameliorated the extrinsic apoptotic pathways *in vivo*. On the other hand, treating HepG2 cells with sodium ascorbate significantly elevated the three illustrating the ability of sodium ascorbate to enhance the apoptotic pathway in tumor cells without affecting normal cells.

Finally, we investigated the cytotoxic effects of sodium ascorbate and cisplatin on HepG2 cell lines by assessing their effect on cell viability and cytotoxicity. The two compounds produced almost similar results, but cisplatin was superior. Sodium ascorbate was previously reported to possess cytotoxic activity against HepG2 \[[@CIT0014],[@CIT0047],[@CIT0048]\]. We have also previously reported the cytotoxic activity of sodium ascorbate both *in vivo* and *in vitro* by restoring normal concentration of HSPGs \[[@CIT0012],[@CIT0015]\]. In addition, sodium ascorbate showed hepatoprotective effects, which were demonstrated by its ability to attenuate HCC-induced inflammatory cells infiltration, apoptotic changes and vacuolations of hepatocytes in hepatic sections stained with hematoxylin/eosin.

5.. Conclusion {#S006}
==============

Sodium ascorbate possesses cytotoxic activity both *in vivo* and *in vitro*. These effects can be partially explained by direct activation of both extrinsic and intrinsic apoptotic pathway in tumor cells independent on its antioxidant and anti-inflammatory activities. However, in normal cells, sodium ascorbate produced protective effects in normal hepatic cells by producing antioxidant, anti-inflammatory and anti-apoptotic effects ([Figure 8](#F0008){ref-type="fig"}). Figure 8.Schematic representation of hepatic protective activity of sodium ascorbate against HCC *in vivo*.
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